Assembly Biosciences (ASMB) Stock: Buy, Sell, or Hold?
ASMB - Assembly Biosciences, Inc
$29.80
-0.66 (-2.17%)
▼
5d:
-17.52%
30d:
+10.13%
90d:
+32.27%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ASMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ASMB is down 17.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ASMB is down 17.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ASMB is currently trading at $29.80, which is considered slightly low relative to its 30-day fair value range of $28.44 to $35.53.
Technical Outlook: Technically, ASMB is in a uptrend. The price is currently testing key support at $29.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.00 (+74.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ASMB is in a uptrend. The price is currently testing key support at $29.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $52.00 (+74.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$28.44 -
$35.53
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.5% below Wall St target ($52.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$28.44 -
$35.53
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$29.68
Resistance Level
$37.01
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.50
Wall Street Target
$52.00
(+74.5%)
Revenue Growth (YoY)
38.9%
Profit Margin
-0.1%
Share & Embed Analysis
Last updated: September 12, 2026 8:15 PM ET
Data refreshes hourly during market hours. Next update: 9:15 PM
Data refreshes hourly during market hours. Next update: 9:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
